Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
Clarity is the first company to develop the perfect pairing of next-generation theranostic (therapeutic and diagnostic) products using two isotopes of copper. Clarity's lead compound, SARTATE™, is in clinical development focused on neuroblastoma and neuroendocrine tumours. Following excellent pre-clinical data on its SAR-bisPSMA product, the prostate cancer market is a key focus for Clarity, with clinical trials planned for 2020. Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment and has the potential to provide multiple benefits in comparison to current products. Clarity’s SAR-BBN product is also entering clinical development in 2020 in patients with breast and prostate cancer. SAR-BBN is a pan cancer target that holds potential of improving treatment outcomes in such large patient indications such as prostate, ovarian and breast cancer.